Gaelic Laboratories Limited has acquired Athlone Laboratories Limited for an undisclosed amount. Athlone Laboratories, established in the Republic of Ireland in 1974, has been a leading European developer, manufacturer, and exporter of a broad range of oral dose beta-lactam products. This corporate acquisition marks a significant strategic expansion for Gaelic Laboratories, directly integrating Athlone's established market presence and specialized manufacturing capabilities.
Athlone Laboratories operates as an accredited supplier to numerous blue-chip customer partners across Europe, Asia-Pacific, Canada, the Middle East, and South America. Its core competencies include demonstrated manufacturing excellence in beta-lactam technology, producing tablets, capsules, and dry powder oral medications. The company also functions as an established and accredited Global Contract Manufacturing Organization (CMO), known for its flexibility, responsiveness, and capability for smaller batch sizes.
The acquisition by Gaelic Laboratories is strategic, aiming to leverage Athlone’s nearly five decades of experience and its robust global customer base. Gaelic will gain access to Athlone's excellence in technology transfer, its centralized center for technical support, and its expertise in regulatory affairs, pharmacovigilance, stability, and contract analysis. Athlone's membership in the AMR Industry Alliance further underscores its commitment to responsible practices in antibiotic manufacturing.
Expected synergies from this integration include an expanded product portfolio for Gaelic Laboratories within the oral dose beta-lactam market and enhanced operational capabilities. By combining resources, the newly formed entity is poised to capitalize on Athlone's continuous strategic investment and expansion programs, aiming to develop new products and strengthen its technological base. This move is designed to reinforce Gaelic Laboratories’ market position and drive competitive advantage globally.